TDMS Study 92012-06 Pathology Tables
NTP Experiment-Test: 92012-06 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT18
Study Type: CHRONIC WITH AVERAGE SEVERITY GRADES[b] Date: 02/24/03
Route: DOSED FEED 2-METHYLIMIDAZOLE Time: 15:09:13
27 WEEK SSAC/FINAL#1 MICE
Facility: Southern Research Institute
Chemical CAS #: 693-98-1
Lock Date: 10/16/01
Cage Range: All
Reasons For Removal: 25017 Scheduled Sacrifice
Removal Date Range: All
Treatment Groups: Include All
a Number of animals examined microscopically at site and number of animals with lesion
b Average severity grade (1-minimal;2-mild;3-moderate;4-marked)
Page 1
NTP Experiment-Test: 92012-06 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT18
Study Type: CHRONIC WITH AVERAGE SEVERITY GRADES[b] Date: 02/24/03
Route: DOSED FEED 2-METHYLIMIDAZOLE Time: 15:09:13
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE 0PPM 625 PPM 1250 PPM 2500 PPM
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY
Animals Initially In Study 60 60 60 60
Scheduled Sacrifice 10 10 10 10
Early Deaths
Survivors
Animals Examined Microscopically 10 10 10 10
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM
Liver (10) (10) (10) (10)
Hematopoietic Cell Proliferation 1 [1.0]
Infiltration Cellular, Mixed Cell 6 [1.0] 7 [1.0] 3 [1.0] 5 [1.0]
Necrosis, Focal 1 [1.0]
Hepatocyte, Vacuolization Cytoplasmic 1 [2.0] 2 [2.0] 4 [2.0]
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM
None
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM
Adrenal Cortex (10) (10) (10) (10)
Accessory Adrenal Cortical Nodule 2 [3.0] 1 [3.0]
Thyroid Gland (8) (10) (10) (10)
Follicular Cell, Hypertrophy 8 [1.0] 10 [1.1] 10 [1.7]
____________________________________________________________________________________________________________________________________
GENERAL BODY SYSTEM
None
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM
Ovary (10) (10) (10) (10)
Cyst 1 [3.0] 1 [3.0]
Uterus (10) (10) (10) (10)
Hyperplasia, Cystic 3 [1.7] 1 [2.0] 4 [2.3] 1 [2.0]
a Number of animals examined microscopically at site and number of animals with lesion
b Average severity grade (1-minimal;2-mild;3-moderate;4-marked)
Page 2
NTP Experiment-Test: 92012-06 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT18
Study Type: CHRONIC WITH AVERAGE SEVERITY GRADES[b] Date: 02/24/03
Route: DOSED FEED 2-METHYLIMIDAZOLE Time: 15:09:13
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE 0PPM 625 PPM 1250 PPM 2500 PPM
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM
Lymph Node, Mandibular (10) (10) (10) (10)
Pigmentation 2 [2.0] 1 [2.0] 2 [2.0]
Spleen (10) (10) (10) (10)
Hematopoietic Cell Proliferation 2 [1.0] 5 [1.2] 6 [1.5] 10 [2.6]
Pigmentation 1 [1.0] 3 [1.0] 7 [1.3] 10 [1.9]
Lymphoid Follicle, Atrophy 4 [1.5]
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM
Skin (10) (10) (10) (10)
Inflammation, Chronic 1 [2.0]
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM
None
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM
None
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM
Lung (10) (10) (10) (10)
Hyperplasia, Lymphoid 1 [2.0]
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM
None
____________________________________________________________________________________________________________________________________
URINARY SYSTEM
Kidney (10) (10) (10) (10)
Nephropathy 1 [1.0] 1 [1.0]
a Number of animals examined microscopically at site and number of animals with lesion
b Average severity grade (1-minimal;2-mild;3-moderate;4-marked)
Page 3
NTP Experiment-Test: 92012-06 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT18
Study Type: CHRONIC WITH AVERAGE SEVERITY GRADES[b] Date: 02/24/03
Route: DOSED FEED 2-METHYLIMIDAZOLE Time: 15:09:13
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE 0PPM 625 PPM 1250 PPM 2500 PPM
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY
Animals Initially In Study 60 60 60 60
Scheduled Sacrifice 10 10 10 10
Early Deaths
Survivors
Animals Examined Microscopically 10 10 10 10
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM
Liver (10) (10) (10) (10)
Hematopoietic Cell Proliferation 1 [1.0]
Infiltration Cellular, Mixed Cell 2 [1.0] 3 [1.0] 6 [1.0] 2 [1.0]
Necrosis, Focal 1 [1.0]
Hepatocyte, Karyomegaly 5 [1.2]
Hepatocyte, Vacuolization Cytoplasmic 4 [2.0]
Mesentery (1)
Fat, Necrosis 1 [2.0]
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM
Heart (10) (10) (10) (10)
Valve, Hypertrophy 1 [2.0]
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM
Adrenal Cortex (10) (10) (10) (10)
Accessory Adrenal Cortical Nodule 2 [3.0] 1 [3.0]
Hyperplasia, Focal 1 [2.0]
Hypertrophy, Focal 1 [2.0]
Thyroid Gland (10) (10) (10) (10)
Follicle, Cyst 1 [3.0]
Follicular Cell, Hypertrophy 5 [1.0] 9 [1.2] 10 [1.8]
____________________________________________________________________________________________________________________________________
GENERAL BODY SYSTEM
None
____________________________________________________________________________________________________________________________________
a Number of animals examined microscopically at site and number of animals with lesion
b Average severity grade (1-minimal;2-mild;3-moderate;4-marked)
Page 4
NTP Experiment-Test: 92012-06 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT18
Study Type: CHRONIC WITH AVERAGE SEVERITY GRADES[b] Date: 02/24/03
Route: DOSED FEED 2-METHYLIMIDAZOLE Time: 15:09:13
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE 0PPM 625 PPM 1250 PPM 2500 PPM
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM
Preputial Gland (10) (10) (10) (10)
Cyst 1 [3.0]
Inflammation, Chronic 1 [2.0]
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM
Bone Marrow (10) (10) (10) (10)
Hyperplasia 1 [3.0] 2 [2.0] 5 [1.8]
Spleen (10) (10) (10) (10)
Hematopoietic Cell Proliferation 5 [1.0] 10 [2.1] 10 [3.0]
Pigmentation 1 [1.0] 10 [1.1] 10 [2.2]
Lymphoid Follicle, Atrophy 5 [1.2] 10 [1.0]
Lymphoid Follicle, Hyperplasia 1 [1.0]
Thymus (10) (10) (10) (10)
Atrophy 1 [2.0]
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM
None
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM
None
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM
None
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM
Lung (10) (10) (10) (10)
Hemorrhage 1 [2.0] 1 [1.0]
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM
a Number of animals examined microscopically at site and number of animals with lesion
b Average severity grade (1-minimal;2-mild;3-moderate;4-marked)
Page 5
NTP Experiment-Test: 92012-06 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT18
Study Type: CHRONIC WITH AVERAGE SEVERITY GRADES[b] Date: 02/24/03
Route: DOSED FEED 2-METHYLIMIDAZOLE Time: 15:09:13
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE 0PPM 625 PPM 1250 PPM 2500 PPM
____________________________________________________________________________________________________________________________________
None
____________________________________________________________________________________________________________________________________
URINARY SYSTEM
Kidney (10) (10) (10) (10)
Cyst 1 [4.0]
Hydronephrosis 1 [2.0] 1 [2.0]
Nephropathy 1 [1.0] 1 [1.0] 2 [1.0]
Renal Tubule, Pigmentation 1 [1.0] 10 [2.2]
Urinary Bladder (10) (10) (10) (10)
Transitional Epithelium, Hyperplasia 1 [2.0]
a Number of animals examined microscopically at site and number of animals with lesion
b Average severity grade (1-minimal;2-mild;3-moderate;4-marked)
Page 6
------------------------------------------------------------
---------- END OF REPORT ----------
------------------------------------------------------------